Questcor Pharmaceuticals (FRA:QPH) 9-Day RSI : N/A (As of Jul. 05, 2025)

View and export this data going back to . Start your Free Trial

What is Questcor Pharmaceuticals 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2025-07-05), Questcor Pharmaceuticals's 9-Day RSI is N/A.

The industry rank for Questcor Pharmaceuticals's 9-Day RSI or its related term are showing as below:

FRA:QPH's 9-Day RSI is not ranked ^*
in the Biotechnology industry.
Industry Median: 51.18
* Ranked among companies with meaningful 9-Day RSI only.

Competitive Comparison of Questcor Pharmaceuticals's 9-Day RSI

For the Biotechnology subindustry, Questcor Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Questcor Pharmaceuticals's 9-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Questcor Pharmaceuticals's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Questcor Pharmaceuticals's 9-Day RSI falls into.

Save Embed

;

Save Embed

;

Questcor Pharmaceuticals (FRA:QPH) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI

100

–

[ 100

( 1 + Average Gain

Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Questcor Pharmaceuticals (FRA:QPH) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

Questcor Pharmaceuticals 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Questcor Pharmaceuticals's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.

Questcor Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Questcor Pharmaceuticals Inc (FRA:QPH) » Definitions » 9-Day RSI

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.questcor.com

Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.

Questcor Pharmaceuticals Headlines

No Headlines